Back to Search
MARK BLASKOVICH, D.M.D.
D.M.D.
General Practice Dentistry
NPI: 1780930073Individual
Specialties, Licenses & Credentials
General Practice DentistryPrimary
Dentist — General Practice
Code: 1223G0001X
28248(TX)DEN.00201877(CO)
Research & Publications (20)
Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
PMID 12649187·Cancer Res·2003
7-preclinical
Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice.
PMID 11017044·Nat Biotechnol·2000
7-preclinical
Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase.
PMID 19246009·Chem Biol·2009
7-preclinical
Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy.
PMID 19204084·Mol Cell Biol·2009
7-preclinical
Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling.
PMID 18791165·Blood·2008
5-case
Module assembly for protein-surface recognition: geranylgeranyltransferase I bivalent inhibitors for simultaneous targeting of interior and exterior protein surfaces.
PMID 18200641·Chemistry·2008
8-other
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.
PMID 17463090·Proc Natl Acad Sci U S A·2007
7-preclinical
Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I.
PMID 17314046·Bioorg Med Chem Lett·2007
8-other
Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
PMID 16909123·Oncogene·2007
8-other
Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I.
PMID 16633570·Org Biomol Chem·2006
7-preclinical
Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase.
PMID 16446806·Org Biomol Chem·2006
7-preclinical
Activation of dendritic cells via inhibition of Jak2/STAT3 signaling.
PMID 16177074·J Immunol·2005
7-preclinical
Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors.
PMID 15897913·Oncogene·2005
7-preclinical
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.
PMID 15735720·Oncogene·2005
7-preclinical
Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I.
PMID 15653335·Bioorg Med Chem·2005
7-preclinical
In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability.
PMID 15556768·Bioorg Med Chem·2004
7-preclinical
Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening.
PMID 15350512·J Immunol Methods·2004
8-other
Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
PMID 15150116·Cancer Res·2004
7-preclinical
The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
PMID 14593715·Prog Cell Cycle Res·2003
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 120 S CRESCENT DR
PUEBLO WEST, CO 81007 - Phone
- (719) 647-9433
Quick Facts
- NPI
- 1780930073
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile